Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rebamipide liquid for chemoradiotherapy-induced oral mucositis in head and neck cancer
NCT02085460Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Mar 2014
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rebamipide in oral mucositis (OM) (3 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Incidence of Grade >=3 Oral Mucositis Determined by Clinical Examination and Assessed by Central Review According to the Common Terminology Criteria of Adverse Events (CTCAE) Version 3.0 at 77 days. Started Mar 2014; status: completed.
02
Drugs
rebamipide
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT02085460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02085460.